Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLUTICASONE FUROATE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (R03BA) — coverage varies; not interchangeable

  • Beclomethasone dipropionate (Qvar): general benefit
  • Budesonide (Pulmicort Nebuamp): general benefit, Limited Use 260, 261, 262, 263, 264
  • Ciclesonide (Alvesco): general benefit
  • Fluticasone (Flovent HFA): general benefit
  • Mometasone furoate (Asmanex Twisthaler): general benefit

Arnuity Ellipta · DIN 02446561 · 100mcg · Blister dry-powder inhaler, 30 doses

General benefitMarketed · checked 2026-09-19
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Arnuity Ellipta · DIN 02446561 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2016-09-29 Health Canada: Marketed since 2016-01-26 · brand ARNUITY ELLIPTA · ATC R03BA09 FLUTICASONE FUROATE · form Powder · route Inhalation, Oral · ingredients FLUTICASONE FUROATE 100 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Arnuity Ellipta: Formulary list price $51.7800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $51.7800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93200 · Verify on the e-Formulary ↗ (DIN 02446561)

Source record
DIN 02446561: Arnuity Ellipta Raw flags: sec3=Y Item: 680400111; group id 710; item number 1750; lccId None; manufacturer id GSK Source form: Blister Pd Inh-30 Dose Pk; strength: 100mcg Recorded listing: General benefit Source prices (unrounded): $51.7800; ministry $51.7800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02446561 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93200
Shortage status: resolved shortage (ended 2025-12-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02446561
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Arnuity Ellipta · DIN 02446588 · 200mcg · Blister dry-powder inhaler, 30 doses

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Arnuity Ellipta · DIN 02446588 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2016-09-29 Health Canada: Marketed since 2015-12-14 · brand ARNUITY ELLIPTA · ATC R03BA09 FLUTICASONE FUROATE · form Powder · route Inhalation, Oral · ingredients FLUTICASONE FUROATE 200 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Arnuity Ellipta: Formulary list price $103.5200/unit (unit not stated in source; not the patient's cost)

Ministry pays: $103.5200 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93201 · Verify on the e-Formulary ↗ (DIN 02446588)

Source record
DIN 02446588: Arnuity Ellipta Raw flags: sec3=Y Item: 680400112; group id 710; item number 1751; lccId None; manufacturer id GSK Source form: Blister Pd Inh-30 Dose Pk; strength: 200mcg Recorded listing: General benefit Source prices (unrounded): $103.5200; ministry $103.5200 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02446588 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93201
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02446588
Shortage record checked 2026-09-13T08:10:21.292534+00:00

FLUTICASONE FUROATE & UMECLIDINIUM BROMIDE & VILANTEROL TRIFENATATE

All products: Limited Use (codes 567)

Other products in the same Health Canada class (R03BA) — coverage varies; not interchangeable

  • Beclomethasone dipropionate (Qvar): general benefit
  • Budesonide (Pulmicort Nebuamp): general benefit, Limited Use 260, 261, 262, 263, 264
  • Ciclesonide (Alvesco): general benefit
  • Fluticasone (Flovent HFA): general benefit
  • Mometasone furoate (Asmanex Twisthaler): general benefit

Trelegy Ellipta · DIN 02474522 · 100mcg & 62.5mcg & 25mcg · dry-powder inhaler, 30 doses

Limited Use — Reason for Use code 567 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 567 required
Write on scriptLU code 567 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 567
Reason for Use code 567 For the long-term, once daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD in patients with a history of exacerbations in patients who require a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA). Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Trelegy Ellipta · DIN 02474522 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2019-09-30 Health Canada: Marketed since 2018-05-30 · brand TRELEGY ELLIPTA · ATC R03AL08 VILANTEROL, UMECLIDINIUM BROMIDE AND FLUTICASONE FUROATE, R03AL08 VILANTEROL, UMECLIDINIUM BROMIDE AND FLUTICASONE FUROATE, R03AL08 VILANTEROL, UMECLIDINIUM BROMIDE AND FLUTICASONE FUROATE · form Powder · route Inhalation · ingredients UMECLIDINIUM (UMECLIDINIUM BROMIDE) 62.5 MCG/ACT, VILANTEROL (VILANTEROL TRIFENATATE) 25 MCG/ACT, FLUTICASONE FUROATE 100 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Trelegy Ellipta: Formulary list price $137.6700/unit (unit not stated in source; not the patient's cost)

Ministry pays: $137.6700 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96469 · Verify on the e-Formulary ↗ (DIN 02474522)

Source record
DIN 02474522: Trelegy Ellipta Raw flags: sec12=Y, sec3=Y Item: 121200114; group id 223; item number 0401; lccId 00321; manufacturer id GSK Source form: Pd Inh-30 Dose Pk; strength: 100mcg & 62.5mcg & 25mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $137.6700; ministry $137.6700 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474522 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96469 Therapeutic Notes (formulary) Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Shortage status: resolved shortage (ended 2023-01-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474522
Shortage record checked 2026-09-13T08:10:21.292534+00:00

FLUTICASONE FUROATE & VILANTEROL

All products: Limited Use (codes 330, 456)

Other products in the same Health Canada class (R03BA) — coverage varies; not interchangeable

  • Beclomethasone dipropionate (Qvar): general benefit
  • Budesonide (Pulmicort Nebuamp): general benefit, Limited Use 260, 261, 262, 263, 264
  • Ciclesonide (Alvesco): general benefit
  • Fluticasone (Flovent HFA): general benefit
  • Mometasone furoate (Asmanex Twisthaler): general benefit

Breo Ellipta · DIN 02408872 · 100mcg & 25mcg · Blister dry-powder inhaler, 30 doses

Limited Use — Reason for Use code 330, 456 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 330, 456 required
Write on scriptLU code 330, 456 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330, 456
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 456 For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have a history of exacerbations and have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)). Coverage limit: LU Authorization Period: Indefinite Coverage limit: COPD disease severity is based on spirometry, symptoms and disability (see classification below). Classification COPD Stages - Symptoms and disability: Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure Classification by impairment of lung function: COPD stage and spirometry (post bronchodilator) FEV1 predicted: Mild: Greater than or equal to 80 percent Moderate: 50 to 79 percent Severe: 30 to 49 percent Very severe: Less than 30 percent
No interchangeable product listed in the Ontario extract
Breo Ellipta · DIN 02408872 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2015-03-31 Health Canada: Marketed since 2013-11-29 · brand BREO ELLIPTA · ATC R03AK10 VILANTEROL AND FLUTICASONE FUROATE, R03AK10 VILANTEROL AND FLUTICASONE FUROATE · form Powder · route Inhalation · ingredients FLUTICASONE FUROATE 100 MCG/ACT, VILANTEROL (VILANTEROL TRIFENATATE) 25 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Breo Ellipta: Formulary list price $112.6000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $112.6000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89362 · Verify on the e-Formulary ↗ (DIN 02408872)

Source record
DIN 02408872: Breo Ellipta Raw flags: sec12=Y, sec3=Y Item: 121200107; group id 224; item number 0402; lccId 00249; manufacturer id GSK Source form: Blister Pd Inh-30 Dose Pk; strength: 100mcg & 25mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $112.6000; ministry $112.6000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408872 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89362
Shortage status: resolved shortage (ended 2023-01-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02408872
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Breo Ellipta · DIN 02444186 · 200mcg & 25mcg · Blister dry-powder inhaler, 30 doses

Limited Use — Reason for Use code 330 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 330 required
Write on scriptLU code 330 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Breo Ellipta · DIN 02444186 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2016-08-30 Health Canada: Marketed since 2015-10-02 · brand BREO ELLIPTA · ATC R03AK10 VILANTEROL AND FLUTICASONE FUROATE, R03AK10 VILANTEROL AND FLUTICASONE FUROATE · form Powder · route Inhalation · ingredients FLUTICASONE FUROATE 200 MCG/ACT, VILANTEROL (VILANTEROL TRIFENATATE) 25 MCG/ACT · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Breo Ellipta: Formulary list price $175.1600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $175.1600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92906 · Verify on the e-Formulary ↗ (DIN 02444186)

Source record
DIN 02444186: Breo Ellipta Raw flags: sec12=Y, sec3=Y Item: 121200111; group id 225; item number 0403; lccId 00268; manufacturer id GSK Source form: Blister Pd Inh-30 Dose Pk; strength: 200mcg & 25mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $175.1600; ministry $175.1600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02444186 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92906
Shortage status: resolved shortage (ended 2023-01-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02444186
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (12:12 Sympathomimetic (Adrenergic) Agents) and how they are covered

Matched class: 12:12 Sympathomimetic (Adrenergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE, SALBUTAMOL 12:12 Sympathomimetic (Adrenergic) Agents

EPINEPHRINE HCL

· 1 products · General benefit · strengths: 30mg/30mL · Inj Sol-30mL Pk

ORCIPRENALINE SULFATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2mg/mL · O/L

SALBUTAMOL

· 20 products · Limited Use, codes 265, 266, 267, 268 (4), Listed, not a benefit (8), Limited Use, codes 256, 257, 258, 259 (1), General benefit (7) · strengths: 1mg/mL, 2mg/mL, 5mg/mL, 100mcg/Metered Dose, 2mg, 4mg · Inh Sol- 2.5mL Pk, Inh Sol-10mL Pk, Inh-200 dose Pk, Tab

TERBUTALINE SULFATE

· 2 products · General benefit · strengths: 0.5mg/Dose · Inh-100 Dose Pk, Inh-120 Dose Pk

ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 459 · strengths: 400mcg & 12mcg · Metered Dose Pd Inh-60 Dose Pk

BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg/6mcg, 200mcg/6mcg · Pd Inh-120 Dose Pk

BUDESONIDE&GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE)&FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 638 · strengths: 160mcg & 7.2mcg & 5mcg/Act · Metered Dose Inh-120 Dose Pk

FORMOTEROL FUMARATE

· 1 products · Limited Use, codes 132 · strengths: 12mcg/Cap · Inh Pd-Device Pk

FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 132 · strengths: 6mcg/Metered Dose, 12mcg/Metered Dose · Pd Inh-60 Dose Pk

INDACATEROL

· 1 products · Limited Use, codes 443 · strengths: 75mcg · Inh Pd-Cap

INDACATEROL & GLYCOPYRRONIUM

· 1 products · Limited Use, codes 459 · strengths: 110mcg & 50mcg · Inh Pd-Cap

MOMETASONE FUROATE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg & 5mcg, 200mcg & 5mcg · Metered Dose Inh-120 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:12 and 3 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:20 Skeletal Muscle Relaxants

Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered

Matched class: 68:04 Corticosteroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, HYDROCORTISONE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE 68:04 Corticosteroids

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 50mcg/Metered Dose, 100mcg/Metered Dose · Aero Inh-200 Dose Pk

BUDESONIDE

· 12 products · Limited Use, codes 260, 261, 262, 263, 264 (9), General benefit (3) · strengths: 0.125mg/mL, 0.25mg/mL, 0.5mg/mL, 100mcg/Metered Dose, 200mcg/Metered Dose, 400mcg/Metered Dose · Inh Susp, Pd Inh-200 Dose Pk

CICLESONIDE

· 3 products · General benefit · strengths: 100mcg/Actuation, 200mcg/Actuation, 50mcg/Actuation · Inh-120 Dose Pk, Metered Dose Nas Sp-120 Dose Pk

FLUTICASONE PROPIONATE

· 14 products · General benefit · strengths: 50mcg/Metered Dose, 125mcg/Metered Dose, 250mcg/Metered Dose, 55mcg/Actuation, 113mcg/Actuation, 232mcg/Actuation, 250mcg/Blister, 500mcg/Blister · Inh-120 Dose Pk, Pd Inh-60 Dose Pk

MOMETASONE FUROATE

· 3 products · General benefit · strengths: 400mcg/Metered Dose, 200mcg/Metered Dose · Pd Inh-30 Dose Pk, Pd Inh-60 Dose Pk

DEXAMETHASONE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 0.5mg, 4mg · Tab

DEXAMETHASONE 21-PHOSPHATE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 4mg/mL · Inj Sol

FLUDROCORTISONE ACETATE

· 2 products · General benefit · strengths: 0.1mg · Tab

HYDROCORTISONE

· 5 products · General benefit (4), Temporary benefit (1) · strengths: 10mg, 20mg · Tab

METHYLPREDNISOLONE

· 1 products · General benefit · strengths: 4mg · Tab

METHYLPREDNISOLONE ACETATE

· 3 products · General benefit · strengths: 40mg/mL, 80mg/mL, 100mg/5mL · Inj Susp-1mL Pk, Inj Susp-5mL Pk

PREDNISOLONE SODIUM PHOSPHATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 6.7mg/5mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:04 and 5 more
Full class listing Related classes: 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: asthma, copd, obstructive pulmonary disease, steroid-responsive bronchial asthma
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, CICLESONIDE, GLYCOPYRRONIUM BROMIDE ACLIDINIUM BROMIDE · General benefit INDICATIONS AND CLINICAL USE TUDORZA GENUAIR (aclidinium bromide) is indicated as a long-term maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00067375.PDF; date not captured; DIN 02409720; fetched 2026-09-10 Product monograph ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 459 INDICATIONS AND CLINICAL USE DUAKLIR GENUAIR (aclidinium bromide/formoterol fumarate dihydrate) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA) indicated as a long-term maintenance bronchodilator treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. PM: https://pdf.hres.ca/dpd_pm/00067361.PDF; date not captured; DIN 02439530; fetched 2026-09-10 Product monograph BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 330 INDICATIONS AND CLINICAL USE Asthma SYMBICORT TURBUHALER (budesonide and formoterol fumarate dihydrate) is indicated for the treatment of asthma in patients 12 years and older with reversible obstructive airways disease. PM: https://pdf.hres.ca/dpd_pm/00059997.PDF; date February 8, 2021; DIN 02245385; fetched 2026-09-10 Product monograph CICLESONIDE · General benefit INDICATIONS AND CLINICAL USE ALVESCO (ciclesonide) is indicated for:  prophylactic management of steroid-responsive bronchial asthma in adults, adolescents and children 6 years of age and older. PM: https://pdf.hres.ca/dpd_pm/00060608.PDF; date March 30, 2021; DIN 02285606; fetched 2026-09-10 Product monograph FLUTICASONE PROPIONATE · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (14) 1 INDICATIONS FLOVENT (fluticasone propionate) is indicated for:  the prophylactic management of steroid-responsive bronchial asthma in adults and children (12 months of age or older). PM: https://pdf.hres.ca/dpd_pm/00060119.PDF; date March 1, 2021; DIN 02237246; fetched 2026-09-10 Product monograph GLYCOPYRRONIUM BROMIDE · General benefit 1 INDICATIONS SEEBRI ® BREEZHALER ® (glycopyrronium bromide) is indicated as a long-term once-daily maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00067963.PDF; date October 16, 2012; DIN 02394936; fetched 2026-09-10 Product monograph INDACATEROL & GLYCOPYRRONIUM · Limited Use, codes 459 1 INDICATIONS ULTIBRO BREEZHALER (indacaterol maleate and glycopyrronium bromide) is a combination of a long- acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and for the reduction of exacerbations of COPD in patients with a history of exacerbations. PM: https://pdf.hres.ca/dpd_pm/00072513.PDF; date Dec 23, 2013; DIN 02418282; fetched 2026-09-10 Product monograph INDACATEROL ACETATE & MOMETASONE FUROATE · Limited Use, codes 626 1 INDICATIONS ATECTURA BREEZHALER (indacaterol/mometasone furoate) is a combination of a long-acting beta2- adrenergic agonist (LABA) and an inhaled corticosteroid (ICS) indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease. PM: https://pdf.hres.ca/dpd_pm/00063537.PDF; date May 5, 2020; DIN 02498685; fetched 2026-09-10 Product monograph MOMETASONE FUROATE & FORMOTEROL FUMARATE DIHYDRATE · Limited Use, codes 330 1 Indications ZENHALE® (mometasone furoate / formoterol fumarate dihydrate inhalation aerosol), is a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) indicated for: • the treatment of asthma, in patients 12 years of age and older with reversible obstructive airway disease. PM: https://pdf.hres.ca/dpd_pm/00080784.PDF; date 2025-06-09; DIN 02361752; fetched 2026-09-10 Product monograph SALMETEROL XINAFOATE & FLUTICASONE PROPIONATE · Limited Use, codes 330 Chronic Obstructive Pulmonary Disease (COPD) ADVAIR DISKUS 250 and ADVAIR DISKUS 500 are indicated for:  the maintenance treatment of COPD, including emphysema and chronic bronchitis, in patients where the use of a combination product is considered appropriate. PM: https://pdf.hres.ca/dpd_pm/00056976.PDF; date June 17, 2020; DIN 02240835; fetched 2026-09-10 Product monograph and 4 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS ARNUITY ELLIPTA (fluticasone furoate) is indicated for the once-daily maintenance treatment of steroid-responsive bronchial asthma in patients aged 12 years and older. ARNUITY ELLIPTA is not indicated for the relief of acute bronchospasm (see 7 WARNINGS AND PRECAUTIONS, General, Acute Asthma episodes). 1.1 Pediatrics Pediatrics (< 12 years of age): The safety and efficacy of ARNUITY ELLIPTA have not been established in children less than 12 years of age. 1.2 Geriatrics Geriatrics ( 65 years of age): No dosage adjustment is required in patients over 65 years of age. https://pdf.hres.ca/dpd_pm/00072514.PDF PM date: September 21, 2015 Source product: ARNUITY ELLIPTA; DIN 02446561; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol) is a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA). COPD TRELEGY ELLIPTA 100/62.5/25 mcg is indicated in adult patients who are not adequately treated by a combination of an ICS/LABA or a combination of a LAMA/LABA: • for the long-term, once daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema (see 14 CLINICAL TRIALS). • to reduce exacerbations of COPD in patients with a history of exacerbations (see 14 CLINICAL TRIALS). TRELEGY ELLIPTA is not indicated for the relief of acute bronchospasm (see 7 WARNINGS AND PRECAUTIONS, General). Asthma TRELEGY ELLIPTA 100/62.5/25 mcg and 200/62.5/25 mcg are indicated for the long-term, once-daily, maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a maintenance combination of a medium or high dose of an ICS and a LABA (see 14 CLINICAL TRIALS). TRELEGY ELLIPTA is not indicated for … https://pdf.hres.ca/dpd_pm/00072451.PDF PM date: April 3, 2018 Source product: TRELEGY ELLIPTA; DIN 02474522; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE COPD BREO ELLIPTA (fluticasone furoate/vilanterol) 100/25 mcg is a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA 100/25 mcg once daily is the only strength indicated for the treatment of COPD. BREO ELLIPTA 200/25 mcg is not indicated for patients with COPD. There is no additional benefit of the 200/25 mcg dose compared to the 100/25 mcg dose and there is a potential increased risk of pneumonia and systemic corticosteroid-related adverse reactions. BREO ELLIPTA is not indicated for the relief of acute bronchospasm (see WARNINGS AND PRECAUTIONS, General). Page 3 of 74 Asthma BREO ELLIPTA 100/25 mcg and BREO ELLIPTA 200/25 mcg are indicated for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reve… https://pdf.hres.ca/dpd_pm/00049111.PDF PM date: January 7, 2019 Source product: BREO ELLIPTA; DIN 02408872; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.